{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:25:09Z","timestamp":1787109909430,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":4674,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.anpedi.2013.03.015","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T07:19:05Z","timestamp":1369984745000},"page":"329.e1-329.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Actualizaci\u00f3n del tratamiento con L-asparraginasa en Pediatr\u00eda"],"prefix":"10.1016","volume":"79","author":[{"given":"C.","family":"Moscard\u00f3 Guilleme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sevilla Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Astigarraga Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rives Sol\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"S\u00e1nchez de Toledo Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Fuster Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Parra Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Molina Garica\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gonz\u00e1lez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Madero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2013.03.015_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"Van den Berg","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-Asparaginase treatment in acute lymphoblastic leukemia","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0015","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0020","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0030","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"Pieters","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0035","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0050","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0055","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0065","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.2001.19.5.1297","volume":"19","author":"Rizzari","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0070","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/pbc.22417","article-title":"Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 Protocol between 2000 and 2007","volume":"54","author":"Schrey","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0080","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0085","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-2008-1046540","article-title":"Long-term infusion of L-asparaginase an alternative to intramuscular injection?","volume":"207","author":"Rodriguez","year":"1995","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0095","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/pbc.23380","article-title":"Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly","volume":"59","author":"Pidaparti","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.0306-5251.2001.01464.x","article-title":"Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries","volume":"52","author":"Albertsen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0105","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"Avramis","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0115","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. 2006. [acceso 20 Feb 2009]. Disponible en: http:\/\/ctep.cancer.gov."},{"key":"10.1016\/j.anpedi.2013.03.015_bib0120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mpo.10096","article-title":"Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase","volume":"38","author":"Albertsen","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.03148.x","article-title":"Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system","volume":"115","author":"Albertsen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0130","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0135","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0140","first-page":"600","article-title":"Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl","year":"2009","journal-title":"Clini Adv Hematol Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-008-0026-9","article-title":"The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations","volume":"9","author":"Zalewska-Szewczyk","year":"2009","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0150","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia","volume":"1","author":"Nesbit","year":"1979","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0160","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1,752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.11042","volume":"97","author":"Mitchell","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0170","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V93.5.1595","article-title":"Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors","volume":"93","author":"Nowak-Gottl","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0175","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/s-0037-1613930","article-title":"Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97protocols)","volume":"83","author":"Mauz-Korholz","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0180","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","article-title":"Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration","volume":"101","author":"Nowak-Gottl","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0185","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0195","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/pbc.21037","article-title":"Predicting asparaginase-associated pancreatitis","volume":"49","author":"Knoderer","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0200","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cncr.23716","article-title":"Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic","volume":"113","author":"Morimoto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0205","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/pbc.21721","article-title":"Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia","volume":"51","author":"Wu","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.anpedi.2013.03.015_bib0210","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/blood-2011-07-367904","article-title":"Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials","volume":"118","author":"Willer","year":"2011","journal-title":"Blood"}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403313001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403313001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:35:19Z","timestamp":1787106919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403313001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1695403313001537"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2013.03.015","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n del tratamiento con L-asparraginasa en Pediatr\u00eda","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2013.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}